IAVI
By
IAVI,
Biofabri
Published: Dec. 18, 2023, 4:28 p.m.·
Tags:
Vaccines
- TB kills 1.3 million people a year and sickens more than 10 million people annually.
- A new TB vaccine is needed to reach the global End TB goals.
- MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
- Grant from the Bill & Melinda Gates Foundation to IAVI will support efficacy trial.
NEW YORK, U.S. and PORRIÑO, SPAIN — December 18, 2023 — IAVI, a global nonprofit scientific research organization, and Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, today announced that the Bill & Melinda Gates Foundation has awarded IAVI US$55 million to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults. This funding has been made possible in part through a grant provided by Open Philanthropy, a grant-making organization that aims to use its resources to help others as much as it can. This trial is also supported by additional funding provided by the German Federal Ministry of Education and Research (BMBF) through the KfW Development Bank, which provides funding to IAVI and partners in support of developing MTBVAC. It is anticipated that the trial will begin enrolling participants in mid-2024.
Read More →
By
IAVI
Published: July 7, 2023, 11:34 p.m.·
Tags:
Vaccines,
Research and development
NEW YORK — JULY 6, 2023 — IAVI is pleased to announce a new award has been granted by the German government to help support the late-stage development of a promising tuberculosis (TB) vaccine candidate, MTBVAC.
Read More →
By
IAVI
Published: May 17, 2023, 10:42 p.m.·
Tags:
Vaccines
- TB kills 1.6 million people a year, causing more deaths than any other single infectious disease apart from COVID-19, and sickens more than 10 million people annually.
- A new TB vaccine is needed to reach global END TB goals.
- MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
PORRIÑO, SPAIN, and NEW YORK, U.S. — MAY 17, 2023 — Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, and IAVI, an international nonprofit research organization focused on developing vaccines and antibodies against infectious and neglected diseases, today announced the signing of an agreement for end-to-end development of the tuberculosis (TB) vaccine candidate MTBVAC. This agreement provides a framework for the future of the collaboration that the partners first announced in 2021.
Read More →
By
Moderna, Inc.,
IAVI
Published: April 7, 2022, 4:46 p.m.·
Tags:
Scientific research,
Research and development,
Vaccines
NEW YORK, NY and CAMBRIDGE, MA / April 7, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI today announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats. These diseases - HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19 - are estimated to have caused at least 95 million new infections and more than 4 million deaths in 2020 alone. The collaboration combines the power of Moderna's mRNA platform and IAVI's expertise in discovery and product development to advance vaccines and antibodies designed to be globally accessible, especially in low-income countries where the targeted diseases have high incidence and prevalence.
Read More →
By
FIND,
TB Alliance,
IAVI
Published: April 4, 2022, 4:59 p.m.·
Tags:
Global TB response
On 11 April 2022, FIND, the global alliance for diagnostics, TB Alliance and the International AIDS Vaccine Initiative (IAVI) will host a webinar bringing together a panel of experts to review both new and experimental tools that have the potential to end TB for good, and what is needed to bring them to scale and achieve public health impact.
Read More →
By
IAVI
Published: Dec. 17, 2021, 5:59 p.m.·
Tags:
Vaccines,
Advocacy
The International AIDS Vaccine Initiative (IAVI) announced a social media fellowship starting the last week of January 2022.
Read More →
By
IAVI,
Zendal
Published: July 14, 2021, 9:26 a.m.·
Tags:
Vaccines,
Scientific research,
Research and development
-- TB kills 1.4 million people a year, an infectious disease toll only recently surpassed by COVID-19.
-- COVID-19 has reversed years of progress in TB response, costing additional lives and adding to the urgency of the global TB problem.
-- MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
Read More →
By
TBVI,
IAVI
Published: June 14, 2021, 2:35 p.m.·
Tags:
Vaccines
Read More →
By
GSK,
IAVI
Published: Oct. 29, 2019, 7:40 p.m.·
Tags:
Vaccines,
Scientific research
-- Final analysis of phase IIb study published today in the New England Journal of Medicine and presented at the 50th Union World Conference on Lung Health.
-- Final results confirm the innovative TB candidate vaccine’s efficacy level and acceptable safety profile in three-year clinical trial conducted in sub-Saharan African regions.
Read More →
Page 1 of 1 · Total posts: 9
1